Beyond Air Appoints Dan Moorhead as New CFO

Claim 70% Off TipRanks This Holiday SeasonUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialBeyond Air ( (XAIR) ) just unveiled an update. On December 24, 2025, Beyond Air’s board approved the appointment of veteran finance executive Daniel (Dan) Moorhead as Chief Financial Officer, principal financial officer and principal accounting officer, effective January 5, 2026, replacing interim CFO and controller Duke Dewrell, who will return to his controller role. Moorhead, formerly CFO of Zynex and Evolving Systems, joined under an employment agreement that includes a $325,000 annual salary, eligibility for a discretionary bonus and equity incentives, and an inducement stock option for 70,000 shares vesting over four years, signaling the company’s effort to strengthen its financial leadership as it scales commercially and prepares for the next phase of LungFit PH’s rollout and broader nitric oxide-based product development. The most recent analyst rating on (XAIR) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page. Spark’s Take on XAIR Stock According to Spark, TipRanks’ AI Analyst, XAIR is a Neutral. The score is held down primarily by weak financial fundamentals (large losses, negative margins, leverage, and pressured cash flow) and a pronounced downtrend in the technical setup. The earnings call provides meaningful positives (raised FY2026 guidance, strong YoY growth, and reduced burn), but these improvements are not yet sufficient to outweigh the current profitability and trend risks, while valuation support is limited due to negative earnings and no dividend data. To see Spark’s full report on XAIR stock, click here. More about Beyond Air Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company focused on harnessing endogenous and exogenous nitric oxide to treat respiratory illnesses, neurological disorders, and solid tumors. Its lead system, LungFit PH, is FDA-approved and CE Marked for treating term and near-term neonates with hypoxic respiratory failure, while additional LungFit systems are in clinical trials for severe lung infections such as viral community-acquired pneumonia, including COVID-19, and nontuberculous mycobacteria. Beyond Air also partners with The Hebrew University of Jerusalem on pre-clinical programs for autism spectrum disorder and other neurological conditions, and its affiliate Beyond Cancer, Ltd. is developing ultra-high-concentration nitric oxide therapies for certain solid tumors. Average Trading Volume: 505,143 Technical Sentiment Signal: Strong Sell Current Market Cap: $5.64M For an in-depth examination of XAIR stock, go to TipRanks’ Overview page.